Based on the key indicators related to NeuroSense Therapeutics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, NeuroSense Therapeutics Ltd may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, NeuroSense Therapeutics' Total Current Assets are fairly stable compared to the past year. Key indicators impacting NeuroSense Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for NeuroSense Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor NeuroSense Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in NeuroSense Therapeutics.
Please note, the imprecision that can be found in NeuroSense Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NeuroSense Therapeutics Ltd. Check NeuroSense Therapeutics' Beneish M Score to see the likelihood of NeuroSense Therapeutics' management manipulating its earnings.
NeuroSense Therapeutics Stock Summary
NeuroSense Therapeutics competes with DiaMedica Therapeutics, Lyra Therapeutics, and Centessa Pharmaceuticals. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining NeuroSense Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuroSense Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeuroSense Therapeutics competition to find correlations between indicators driving NeuroSense Therapeutics's intrinsic value. More Info.
NeuroSense Therapeutics Ltd is regarded fourth in return on equity category among its peers. It also is regarded fourth in return on asset category among its peers . At this time, NeuroSense Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NeuroSense Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
NeuroSense Therapeutics Systematic Risk
NeuroSense Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NeuroSense Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on NeuroSense Therapeutics correlated with the market. If Beta is less than 0 NeuroSense Therapeutics generally moves in the opposite direction as compared to the market. If NeuroSense Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NeuroSense Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NeuroSense Therapeutics is generally in the same direction as the market. If Beta > 1 NeuroSense Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as NeuroSense Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of NeuroSense has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if NeuroSense Therapeutics' financials are consistent with your investment objective using the following steps:
Review NeuroSense Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand NeuroSense Therapeutics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare NeuroSense Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if NeuroSense Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in NeuroSense Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NeuroSense Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NeuroSense Therapeutics growth as a starting point in their analysis.
NeuroSense Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NeuroSense Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NeuroSense Therapeutics Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of NeuroSense Therapeutics Ltd based on widely used predictive technical indicators. In general, we focus on analyzing NeuroSense Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NeuroSense Therapeutics's daily price indicators and compare them against related drivers.
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.